On Thursday, Shares of Petróleo Brasileiro S.A. - Petrobras (NYSE:PBR), gained 0.22% to $9.14, despite crude oil futures fell on Thursday as the World Bank cut its global economic growth forecast, ending a two-day rally triggered by a sharp U.S. inventory drawdown.
On the New York Mercantile Exchange, crude oil for July delivery shed 73 cents, or 1.19%, to trade at $60.70 a barrel during U.S. morning hours after hitting a daily low of $60.47.
Petróleo Brasileiro S.A. Petrobras operates as an integrated energy company in Brazil and internationally. Its Exploration and Production segment engages in the exploration, development, and production of crude oil, natural gas liquids, and natural gas; and sale of crude oil and oil products produced at natural gas processing plants in domestic and foreign markets.
Shares of AbbVie Inc. (NYSE:ABBV), declined -0.29% to $68.04, during its last trading session.
AbbVie, declared updated results of a Phase 1b study that showed patients with relapsed/refractory chronic lymphocytic leukemia (CLL) taking venetoclax, an investigational B-cell lymphoma 2 (BCL-2) selective inhibitor, in combination with rituximab, had an overall response rate (ORR) of 84 percent (n=41/49). Additionally, six patients stopped venetoclax after achieving either a complete response (CR) or CR with incomplete marrow recovery (CRi). Three patients maintained a response after a median of 12 months (0-21). These data were detailed in an oral presentation at the 20th Congress of the European Hematology Association (EHA), June 11-15, in Vienna.
“Potentially, the most interesting part of these initial results is the data regarding the patients who have been able to come off treatment and who continue to maintain their complete response,” said Professor Andrew W. Roberts, MBBS, FRACP, FRCPA, PhD, the Royal Melbourne Hospital Department of Clinical Hematology and Bone Marrow Transplant Service, Australia, and head of Clinical Translation at the Walter and Eliza Hall Institute of Medical Research. “The fact that this investigational venetoclax combination achieved these response rates suggests this treatment may offer patients another option and warrants further investigation.”
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products comprise HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases.
Finally, Schlumberger Limited (NYSE:SLB), ended its last trade with -1.05% loss, and closed at $90.67.
Eurasia Drilling Co. dropped the most in 3 1/2 months in London trading after Russia failed to rule on a planned purchase of the company by Schlumberger Ltd, according to Bloomberg.
Eurasia’s global depositary receipts tumbled as much as 10 percent, the biggest decline since Feb. 20, to $18.10. Trading volumes were 60 percent above the three-month daily average.
Russia’s foreign-investment commission met Thursday yet didn’t make a decision on Schlumberger’s bid, Natural Resources Minister Sergei Donskoi said by phone, without giving a reason. Investors had hoped a ruling would clear the way for the deal’s $1.7 billion first phase, which has already been delayed months. Bloomberg Reports.
Schlumberger, based in Houston and Paris, declared the planned purchase in January as the U.S. and Russia faced off over President Vladimir Putin’s support for a separatist insurgency in Ukraine. U.S. and European sanctions on Russia comprise curbs on exports of drilling technology. Bloomberg added.
Schlumberger Limited supplies technology, integrated project administration, and information solutions to the oil and gas exploration and production industries worldwide. The company operates through Reservoir Characterization Group, Drilling Group, and Production Group segments.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
